Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Clavio M, Crisà E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Santini V. Clavio M, et al. Among authors: catarini m. Cancer. 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19. Cancer. 2021. PMID: 33739457 Free article.
Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes.
Poloni A, Goteri G, Zizzi A, Serrani F, Trappolini S, Costantini B, Mariani M, Olivieri A, Catarini M, Centurioni R, Alesiani F, Giantomassi F, Stramazzotti D, Biagetti S, Alfonsi S, Berardinelli E, Leoni P. Poloni A, et al. Among authors: catarini m. Eur J Haematol. 2013 Sep;91(3):219-227. doi: 10.1111/ejh.12145. Epub 2013 Jun 28. Eur J Haematol. 2013. PMID: 23679560
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: catarini m. Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041. Clin Lymphoma Myeloma. 2008. PMID: 18854284
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A, Alesiani F, Brunori M, Catarini M, Visani G, Samori A, Burattini M, Centurioni R, Montanari M, Fraticelli P, Ruggieri M, Falcioni S, Galieni P. Offidani M, et al. Among authors: catarini m. Eur J Haematol. 2010 Jun;84(6):474-83. doi: 10.1111/j.1600-0609.2010.01418.x. Epub 2010 Mar 11. Eur J Haematol. 2010. PMID: 20331733 Clinical Trial.
Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.
Olivieri A, Gini G, Bocci C, Montanari M, Trappolini S, Olivieri J, Brunori M, Catarini M, Guiducci B, Isidori A, Alesiani F, Giuliodori L, Marcellini M, Visani G, Poloni A, Leoni P. Olivieri A, et al. Among authors: catarini m. Oncologist. 2012;17(5):663-72. doi: 10.1634/theoncologist.2011-0355. Epub 2012 Apr 24. Oncologist. 2012. PMID: 22531362 Free PMC article.
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P. Offidani M, et al. Among authors: catarini m. Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32. doi: 10.1016/j.clml.2012.06.008. Epub 2012 Sep 14. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22981966
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P. Offidani M, et al. Among authors: catarini m. Leuk Lymphoma. 2011 May;52(5):776-85. doi: 10.3109/10428194.2011.555027. Epub 2011 Feb 21. Leuk Lymphoma. 2011. PMID: 21338282
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Offidani M, et al. Among authors: catarini m. Blood. 2006 Oct 1;108(7):2159-64. doi: 10.1182/blood-2006-03-013086. Epub 2006 Jun 8. Blood. 2006. PMID: 16763209 Free article. Clinical Trial.
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Offidani M, Leoni P, Bringhen S, Corvatta L, Larocca A, Gentili S, Oliva S, Polloni C, Galieni P, Catarini M, Alesiani F, Mele A, Brunori M, Blasi N, Ferranti M, Visani G, Boccadoro M, Palumbo A. Offidani M, et al. Among authors: catarini m. Leuk Lymphoma. 2010 Aug;51(8):1444-9. doi: 10.3109/10428194.2010.486878. Leuk Lymphoma. 2010. PMID: 20496998
26 results